The cost-effectiveness of immunochemical tests for colorectal cancer screening

Digestive and Liver Disease

Volumn 46, Issue 1, 2014, Pages 76-81

  Lejeune, Catherine ^a   Le Gleut, Karelle ^b   Cottet, Vanessa ^a,d   Galimard, Christine ^c   Durand, Gerard ^b   Dancourt, Vincent ^a,d   Faivre, Jean ^a,d  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b ICONES   (France)

^c CPAM CÔte d'Or   (France)

^d Chu   (France)

Author keywords

Faecal occult blood tests; Markov model; Mass screening; Medico economic evaluation

Indexed keywords

GUAIAC;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; FECES ANALYSIS; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; POPULATION; PRIORITY JOURNAL; SENSOR;

FAECAL OCCULT BLOOD TESTS; MARKOV MODEL; MASS SCREENING; MEDICO-ECONOMIC EVALUATION;

AGED; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOCHEMISTRY; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD;

EID: 84892159583     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.018     Document Type: Article

References (28)

1. Gyrd-Hansen D., Sogaard J., Kronborg O. Analysis of screening data: colorectal cancer. International Journal of Epidemiology 1997, 26:1172-1181.
2. Launoy G., Smith T.C., Duffy S.W., et al. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. International Journal of Cancer 1997, 73:220-224.
3. Guittet L., Bouvier V., Mariotte N., et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007, 56:210-214.
4. Hol L., Wilschut J.A., van Ballegooijen M., et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. British Journal of Cancer 2009, 100:1103-1110.
5. van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Cut-off value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. British Journal of Cancer 2009, 101:1274-1281.
6. Barouni M., Larizadeh M.H., Sabermahani A., et al. Markov's modeling for screening strategies for colorectal cancer. Asian Pacific Journal of Cancer Prevention 2012, 13:5125-5129.
7. Berchi C., Bouvier V., Réaud J.M., et al. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Economics 2003, 49:3-9. 6.
8. Berchi C., Guittet L., Bouvier V., et al. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. International Journal of Technology Assessment in Health Care 2010, 26:48-53.
9. Chen L.S., Liao C.S., Chang S.H., et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). Journal of Medical Screening 2007, 14:191-199.
10. Goede S.L., van Roon A.H., Reijerink J.C., et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2012, 62:727-734.
11. Sobhani I., Alzahouri K., Ghout I., et al. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Diseases of the Colon and Rectum 2011, 54:876-886.
12. Telford J.J., Levy A.R., Sambrook J.C., et al. The cost-effectiveness of screening for colorectal cancer. CMAJ 2010, 182:1307-1313.
13. van Rossum L.G., van Rijn A.F., Verbeek A.L., et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. International Journal of Cancer 2010, 128:1908-1917.
14. Wilschut J.A., Hol L., Dekker E., et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011, 141:1648-1655.
15. Lejeune C., Arveux P., Dancourt V., et al. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. European Journal of Cancer Prevention 2003, 12:77-84.
16. Faivre J., Dancourt V., Lejeune C., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004, 126:1674-1680.
17. Faivre J., Dancourt V., Denis B., et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. European Journal of Cancer 2012, 48:2969-2976.
18. Faivre J., Dancourt V., Manfredi S., et al. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme. Digestive and Liver Disease 2012, 700-04.
19. Nakama H., Yamamoto M., Kamijo N., et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepato-Gastroenterology 1999, 46:228-231.
20. Rozen P., Comaneshter D., Levi Z., et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010, 116:2115-2125.
21. Rosman A.S., Korsten M.A. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. Journal of General Internal Medicine 2010, 25:1211-1221.
22. Pickhardt P.J., Hassan C., Halligan S., et al. Colorectal cancer: CT colonography and colonoscopy for detection - systematic review and meta-analysis. Radiology 2011, 259:393-405.
23. van Roon A.H., Wilschut J.A., Hol L., et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clinical Gastroenterology and Hepatology 2011, 9:333-339.
24. Lejeune C., Arveux P., Dancourt V., et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. International Journal of Technology Assessment in Health Care 2004, 20:434-439.
25. INCa Institut National du Cancer Synthèse relative aux modalités de migration vers l'utilisation des tests immunologiques de dépistage 2012, http://www.e-cancer.fr/toutes-les-actualites/235/6706-linca-publie-une-synthese-relative-aux-modalites-de-migration-vers-lutilisation-des-tests-immunologiques-de-depistage.
26. INCa Institut National du Cancer Dossier de Presse: campagne de mobilisation pour le dépistage organisé du cancer colorectal 2012, http://www.e-cancer.fr/la-presse/dossiers-de-presse.
27. Pox C.P., Altenhofen L., Brenner H., et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012, 142:1460-1467. e2.
28. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004, 13:437-452.